News | October 25, 2021
Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
Subscribe To Our Newsletter & Stay Updated
